Soleno Therapeutics to Participate in the Guggenheim Healthcare Talks Genomic Medicines and Rare Disease Days
REDWOOD CITY, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks Genomic Medicines and Rare Disease Days on Monday, April 3, 2023 at 10:10 AM Eastern Time.
A live audio webcast and replay of the fireside chat will be available in the Investors section on the Company’s website at www.soleno.life.
About Soleno Therapeutics, Inc.
Meshing Technologies: Managing Wifi and Private 4G/5G with Public Carrier Networks
CCaaS and MSPs: The Perfect Partnership